DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Volanesorsen
Volanesorsen
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
N-Acetyl Galactosamine-Conjugated Antisense Drug to APOC3 Mrna, Triglycerides and Atherogenic Lipoprotein Levels
Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence
Volanesorsen Fdaadvisory Committee Meeting Briefing Document
News from European Society of Cardiology Aug31-Sept4
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Stembook 2018.Pdf
NLA-TG Therapies DIXON
The Importance of Lipoprotein Lipase Regulationin Atherosclerosis
Emerging New Lipid-Lowering Therapies in the Statin Era
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahr 2020
Waylivra, Volanesorsen
The Future of Lipid-Lowering Therapy Willemien Van Zwol, Antoine Rimbert, Jan Kuivenhoven
2015 AHA Apociii Poster
View/Download Slides
Lipid Management in Patients with Endocrine Disorders: an Endocrine
Volanesorsen (Waylivra)
O-(2 Methoxyethyl) Antisense Oligonucleotide, Across Species
Top View
Antisense Oligonucleotides: an Emerging Area in Drug Discovery and Development
FDA Briefing Document Endocrinologic and Metabolic
Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome Or Hypertriglyceridaemia: Design, Development and Place in Therapy
Effects (Critical Role) of Nitrite and Nitrate Determinants in Saliva And
Management of Hypertriglyceridemia BMJ: First Published As 10.1136/Bmj.M3109 on 12 October 2020
World Journal of Cardiology
New Trends in Dyslipidemia Treatment
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lipid Modification to Reduce Cardiovascular Risk
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
Novel Approaches to Lipid-Lowering Therapy
Publication Agenda CHMP 07-10 December 2020
150-499 Mg/Dl) Michael S
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Waylivra, INN-Volanesorsen